![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 14, Issue 4, 1691-1708, April 2003
§
Departments of *Medicine,
The hepatocyte growth factor receptor tyrosine kinase Met promotes
cell dissociation and the inherent morphogenic program of epithelial
cells. In a search for substrates downstream from Met, we have
previously identified the Grb2-associated binder-1 (Gab1) as critical
for the morphogenic program. Gab1 is a scaffold protein that acts to
diversify the signal downstream from the Met receptor through its
ability to couple with multiple signal transduction pathways. Gab1
contains a pleckstrin homology (PH) domain with specificity for
phosphatidylinositol 3,4,5-trisphosphate. The phospholipid
binding capacity of the Gab1 PH domain is required for the localization
of Gab1 at sites of cell-cell contact in colonies of epithelial cells
and for epithelial morphogenesis, suggesting that PH domain-dependent
subcellular localization of Gab1 is a prerequisite for function. We
have investigated the requirement for membrane localization of Gab1 for
biological activity. We show that substitution of the Gab1 PH domain
with the myristoylation signal from the c-Src protein is sufficient to
replace the Gab1 PH domain for epithelial morphogenesis. The membrane
targeting of Gab1 enhances Rac activity in the absence of stimulation
and switches a nonmorphogenic noninvasive response to epidermal growth factor to a morphogenic invasive program. These results suggest that the subcellular localization of Gab1 is a critical determinant for
epithelial morphogenesis and invasiveness.
Biochemistry, and
§Oncology, Molecular Oncology Group, McGill
University Health Centre, McGill University, Montreal, Quebec, H3A 1A1,
Canada
Corresponding author. E-mail address:
morag{at}molonc.mcgill.ca.
This article has been cited by other articles:
![]() |
G. N. Paliouras, M. A. Naujokas, and M. Park Pak4, a Novel Gab1 Binding Partner, Modulates Cell Migration and Invasion by the Met Receptor Mol. Cell. Biol., June 1, 2009; 29(11): 3018 - 3032. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Timpson, A. S. Wilson, G. M. Lehrbach, R. L. Sutherland, E. A. Musgrove, and R. J. Daly Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells Is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Cancer Res., October 1, 2007; 67(19): 9304 - 9314. [Abstract] [Full Text] [PDF] |
||||